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Acute graft-versus-host disease (GVHD) remains a leading cause of morbidity and nonrelapse mortality after
allogeneic hematopoietic cell transplantation. The clinical staging of GVHD varies greatly between transplant
centers and is frequently not agreed on by independent reviewers. The lack of standardized approaches to
handle common sources of discrepancy in GVHD grading likely contributes to why promising GVHD treat-
ments reported from single centers have failed to show beneﬁt in randomized multicenter clinical trials. We
developed guidelines through international expert consensus opinion to standardize the diagnosis and
clinical staging of GVHD for use in a large international GVHD research consortium. During the ﬁrst year of
use, the guidance followed discussion of complex clinical phenotypes by experienced transplant physicians
and data managers. These guidelines increase the uniformity of GVHD symptom capture, which may improve
the reproducibility of GVHD clinical trials after further prospective validation.
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ty for Blood and Marrow Transplantation.INTRODUCTION
The practice of acute graft-versus-host disease (GVHD)
clinical staging varies between transplant centers, and poor
concordance has been recognized for over 25 years, with
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40% to 72% [1,2]. The threshold for diagnosis of GVHD and
quantiﬁcation of symptoms remain variable among centers,
as evidenced by widely disparate cumulative incidences of
grades II to IV GVHD ranging from 40% to 80% after
T cellereplete blood and marrow transplantation (BMT)
[3,4]. The difference in rates are likely due to multiple factors
such as frequency of obtaining target organ biopsies when
symptoms arise, appropriate consideration and application
of measures to exclude alternative diagnoses, and absence of
consensus guidelines to address inherent challenges in
GVHD staging such as stool volume quantiﬁcation. These
variations in practice also result in differences in reporting of
timing of GVHD onset and its severity, which poses a sig-
niﬁcant barrier to the successful conduct of multicenter tri-
als. These barriers can only be overcome through the
consistent application of guidelines to clinical GVHD data
capture that can uniformly be applied by both clinicians and
data managers.
We recently reported a newweb-based remote data entry
system we developed for GVHD data capture that is now
being used in an international GVHD research consortium
(the Mount Sinai Acute GVHD International Consortium, or
MAGIC) [5]. The GVHD staging guidance outlined in this
report was developed initially at a single institution (Uni-
versity of Michigan) and then tested in this multicenter
group for clarity and ease of use. The guidance was then
reﬁned during its ﬁrst year of use through discussion of
complicated cases seen at these centers via international
webinars to reach a consensus opinion. The guidelines out-
lined in this report are not intended to dictate clinical prac-
tice, but rather they are a tool to standardize the collection of
complex clinical data for acute GVHD clinical and trans-
lational research. Although a few controversial topics remain
to be resolved in this evolving guidance, the centers in our
GVHD consortium have found this guidance for GVHD data
collection clearer and easier to use than prior systems, and it
could be used by other centers that conduct GVHD clinical
research.
TARGET ORGAN SYMPTOM CAPTURE
Although the guidelines for GVHD staging by symptom
severity have been well established [6], quantiﬁcation of the
severity of symptoms has not been standardized across
centers. Many databases only record target organ staging,
which limits retrospective review of severity without
examining source documents from the medical record. To
avoid this problem, we collect the absolute quantiﬁcation of
symptoms (extent of skin rash, total bilirubin level, volume of
diarrhea), according to the guidance detailed below,
regardless of suspected/proven etiology.
Skin
The skin is the most commonly involved GVHD target
organ [7], but patients have multiple potential causes for
rash after allogeneic transplantation (eg, GVHD, medications,
viral exanthemata), and the clinical manifestations may not
point to 1 speciﬁc etiology. Rash quantiﬁcation can be clini-
cally challenging, however, because inclusion of all areas of
abnormal skin does not distinguish areas of active inﬂam-
matory erythema that are characteristic of GVHD [8] from
areas of inactive hyperpigmentation or other non-GVHD
changes that may lead to discrepancies in rash quantiﬁca-
tion from 1 clinician to the next. This distinction is important
because the natural course of an erythematous rash whileresolving is to appear hyperpigmented or “browned over.”
For example, a patient may have rash involving 60% body
surface area (BSA) that if included in its entirety would be
classiﬁed as stage 3 skin GVHD. Upon closer inspection,
however, the skin changes may include petechiae, hyper-
pigmentation, and/or other changes not consistent with
active GVHD. If the non-GVHD skin changes account formore
than 10% of the skin changes in this example, the GVHD
would be downgraded to stage 2 skin GVHD, which may
impact the decision to initiate systemic GVHD therapy. Thus,
only areas involved with active erythema should be used for
determination of BSA staging of GVHD using the “rule of
nines” [9].
A portion of a body area segment may be used for the
quantiﬁcation. For example, if erythema is observed only on
the upper half of an arm, this would be quantiﬁed as 4.5%, or
half of the arm’s total 9% BSA. Additionally, one should report
if desquamation or ﬂuid-ﬁlled bullae are present, because
these ﬁndings are the hallmark of stage 4 skin GVHD.
Patients may have occasional blisters or small patches of dry
skin with desquamation that do not reﬂect the massive
inﬂammation implied by stage 4 skin GVHD. Therefore, this
guidance requires both generalized erythema as well as >5%
BSA involvement with blisters and/or desquamation to di-
agnose skin stage 4 GVHD.
Liver
The liver is the least frequently involved acute GVHD
target organ [4,10,11]; however, it is important to document
the presence of liver GVHD because of the poorer prognosis it
portends [12]. Liver GVHD staging is based solely on total
(not conjugated/direct) serum bilirubin levels. Liver GVHD
manifesting as transaminitis without hyperbilirubinemia is
not staged when applying modiﬁed Glucksberg GVHD stag-
ing [6,13,14], and transaminitis from non-GVHD causes is
common after BMT. We therefore only diagnose liver GVHD
manifesting as transaminitis without concomitant elevation
in serum bilirubin when the presence of GVHD is conﬁrmed
by liver biopsy and score it as stage 0. Future revisions to
staging acute liver GVHD presenting as isolated transaminitis
will require correlation of transaminase levels, the diagnoses
under consideration, and treatment decisions with clinical
outcomes.
Because of the relatively infrequent involvement of the
liver at GVHD onset and the fact that patients may have
hyperbilirubinemia from other causes at the onset of GVHD
(eg, chemotherapy toxicity, sinusoidal obstructive syndrome,
parenteral nutritioneassociated cholestasis), if bilirubin
levels were elevated before the diagnosis of GVHD in another
target organ and do not increase further, we do not diagnose
liver GVHD in the absence of biopsy conﬁrmation. If hyper-
bilirubinemia develops at the same time or after the onset of
GVHD in another target organ, however, liver GVHD is pre-
sumed to be present in the absence of an identiﬁed alter-
native cause.
Upper Gastrointestinal Tract
The frequency of GVHD involving the upper gastrointes-
tinal (GI) tract is highly variable between BMT centers, with
incidences ranging from 24% to 60% [3,15]. Symptoms of
concern for upper GI GVHD include anorexia, nausea, vom-
iting, and dyspepsia [16], but these can also be seen
frequently as a result of infection, mucositis, conditioning
regimen toxicity, and/or medication side effect. The timing,
severity, and duration of symptoms sufﬁcient for clinical
Table 1
GVHD Target Organ Staging
Stage Skin (Active Erythema Only) Liver
(Bilirubin)
Upper GI Lower GI (stool output/day)
0 No active (erythematous) GVHD rash <2 mg/dL No or intermittent nausea,
vomiting, or anorexia
Adult: <500 mL/day or <3 episodes/day
Child: <10 mL/kg/day or <4 episodes/day
1 Maculopapular rash
<25% BSA
2-3 mg/dL Persistent nausea,
vomiting or anorexia
Adult: 500-999 mL/day or 3-4 episodes/day
Child: 10-19.9 mL/kg/day or 4-6 episodes/day
2 Maculopapular rash
25-50% BSA
3.1-6 mg/dL Adult: 1000-1500 mL/day or 5-7 episodes/day
Child: 20-30 mL/kg/day or 7-10 episodes/day
3 Maculopapular rash
>50% BSA
6.1-15 mg/dL Adult: >1500 mL/day or >7 episodes/day
Child: >30 mL/kg/day or >10 episodes/day
4 Generalized erythroderma
(>50% BSA) plus bullous formation
and desquamation >5% BSA
>15 mg/dL Severe abdominal pain with or without ileus or
grossly bloody stool (regardless of stool volume).
Overall clinical grade (based on most severe target organ involvement):
Grade 0: No stage 1-4 of any organ.
Grade I: Stage 1-2 skin without liver, upper GI, or lower GI involvement.
Grade II: Stage 3 rash and/or stage 1 liver and/or stage 1 upper GI and/or stage 1 lower GI.
Grade III: Stage 2-3 liver and/or stage 2-3 lower GI, with stage 0-3 skin and/or stage 0-1 upper GI.
Grade IV: Stage 4 skin, liver, or lower GI involvement, with stage 0-1 upper GI.
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depends on close attention to caloric intake and symptom
reporting. Although upper GI biopsy is required by modiﬁed
Glucksberg staging [6], in practice this requirement is often
ignored and could result in under-reporting of the incidence
of upper GI GVHD. Although we encourage clinicians to
obtain upper GI endoscopy whenever possible, we allow for
the diagnosis of upper GI GVHDwithout biopsy conﬁrmation
provided the symptoms meet consensus thresholds for
severity and duration to avoid overdiagnosis of upper GI
GVHD that could occur without a biopsy requirement; we
believe this is of particular importance when patients pre-
sent without GVHD symptoms in additional target organs.
We do not consider GVHD as a possible etiology when
nausea lasts fewer than 3 days, or with fewer than 2 vomiting
episodes per day for at least 2 days, or anorexia without
weight loss.
After making a diagnosis of upper GI GVHD, the clinician
must inquire and document whether symptoms persist,
because these symptoms are very subjective in nature and
must no longer be present to state upper GI GVHD has
resolved. If a patient has lost weight as a result of upper GI
GVHD, his or her weight must be stable or increasingdand
not attributable to ﬂuid overloaddbefore upper GI can be
considered quiescent.Lower GI Tract
Lower GI GVHD is the target organ involvement most
associated with nonrelapse mortality [3,4,7,10,17,18]. Staging
of this target organ relies on accurate measurement of daily
stool volumes and documentation of the presence of hema-
tochezia or severe abdominal pain [6]. Post-BMT diarrhea
often develops in the outpatient setting where stool volumes
cannot be accurately recorded, and stool output is not always
closely measured when patients are in the hospital, either
because patients did not save the stool for quantiﬁcation or
because stool and urine were not collected separately. To
address these barriers, we reviewed hospital ﬂowsheets
from 300 patients with post-transplant diarrhea from both
GVHD and non-GVHD causes that contained both the
measured volume and number of episodes of diarrhea. From
these source documents we calculated an average volume of
200 mL per diarrhea episode for adults or 3 mL/kg forchildren <50 kg (Table 1). Formed or mostly formed stools
should not be quantiﬁed or counted toward diarrhea volume.
To stage lower GI GVHD at onset, we use the highest daily
diarrhea volume during the 3 days before its diagnosis, after
excluding diarrhea volumes attributable to bowel preps for
endoscopy procedures. Because stool volumes may vary
widely from day to day and in response to treatment, after
initiation of treatment we stage lower GVHD based on the
diarrhea volume using (in the order of preference) (1)
average of 3 consecutive days, (2) average of 2 consecutive
days, or (3) the volume on day of assessment.
Finally, severe abdominal pain, ileus, and/or grossly
bloody stool should be documented when present because
stage 4 lower GI GVHD is staged based on the presence of
these symptoms and is independent of volume of diarrhea
[19]. We do not consider streaks of blood in the stool due to
hemorrhoids or anal ﬁssures or transient hematochezia after
endoscopic biopsies when making this determination. The
deﬁnition of severe abdominal pain remains a judgment call
on the part of the treating clinician, but we suggest only
considering pain attributed to GVHD that requires the initi-
ation of high doses of narcotic pain medication or a signiﬁ-
cant increase in ongoing narcotic use and the abdominal pain
signiﬁcantly impacts a patient’s performance status as
determined by the treating clinician.CONFIDENCE LEVELS
Thresholds for initiation of systemic corticosteroids for
treatment of GVHD are variable among centers, particularly
in the setting when no biopsy has been obtained and/or
when only limited skin GVHD is present. These differences in
GVHD diagnosis make it challenging to conduct multicenter
trials because of the difﬁculty determining whether a patient
truly experienced GVHD. To address these varying practices,
we developed a structure for collecting granular GVHD data
and assigning conﬁdence levels for the attribution of symp-
toms to GVHD based on the treatment decisions made by the
clinician. When symptoms develop concerning for GVHD, a
conﬁdence level is assigned to the diagnosis of GVHD as
supported by categorized facts (eg, biopsy results and in-
fectious studies) and by clinical action (Table 2). These con-
ﬁdence levels permit reproducible data reporting and may
facilitate selection of patients for research studies and do not
Table 2
Conﬁdence Level Criteria
Conﬁdence
Level
Pathologic Evidence Clinician Assessment Treatment for
Acute GVHD
Comments
Conﬁrmed Unequivocal pathologic
evidence of GVHD
GVHD is the etiology for symptoms Not applicable GVHD is clearly present even if other etiologies
may coexist simultaneously.
Probable Not required GVHD most likely etiology for
symptoms (as evidenced by
treatment being provided)
Yes GVHD is most likely present, but other
etiologies may also explain the symptoms,
and there is insufﬁcient evidence to make a
conﬁrmed diagnosis.
Possible Not required GVHD in differential diagnosis
(but no treatment is being provided)
No GVHD may be present, but other etiologies
are favored to the degree that GVHD
treatment is not initiated.
Negative Unequivocal evidence
of a diagnosis other
than GVHD (eg, drug rash)
GVHD is not considered as
an explanation for the symptoms
No and the symptoms
resolve without
GVHD treatment
A “negative” biopsy (eg, normal skin) is not
unequivocal evidence of a diagnosis
other than GVHD.
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level is assigned when either there are no active GVHD
symptoms or an alternative etiology is present and treated (if
indicated) and GVHD is not entertained as a possible diag-
nosis. GVHD is deemed possiblewhen a diagnosis of GVHD is
under consideration but not conﬁrmed by biopsy and the
clinical suspicion for GVHD is not sufﬁciently high that the
treating physician initiated GVHD therapy. A conﬁdence level
of probable reﬂects that treatment for GVHD was started
because of sufﬁcient clinical concern but the diagnosis is not
conﬁrmed by biopsy, either because no biopsy was obtained
or because GVHD is not clearly identiﬁed on a biopsy. Finally,
GVHD is considered conﬁrmed if there is unequivocal evi-
dence of GVHD on a biopsy.
Standardization of the determination of GVHD onset is
extremely important for clinical research because onset is
typically reported as a “time-to-event” variable. Using these
conﬁdence levels, GVHD onset is determined to be the date
of initiation of therapy for GVHD or conﬁrmation of GVHD by
biopsy, whichever is earlier. We do not back-date the onset of
GVHD to the onset of symptoms subsequently diagnosed as
GVHD because we cannot exclude the possibility that
symptoms were attributable to an alternative cause when
they ﬁrst appeared only to have GVHD subsequently develop.
The scenario of isolated stage 1 to 2 skin GVHD represents a
special case because many clinicians do not obtain biopsies
or start systemic GVHD therapy, and clinicianswill often start
topical steroid treatment for limited rashes of any cause,
suggesting a lower clinical threshold for initiating topical
therapy than for starting systemic corticosteroid therapy. The
speciﬁcity of skin biopsies for GVHD is also notoriously low,
and pathologic ﬁndings often overlap between GVHD, drug
reaction, and other causes. To standardize onset determina-
tion in this scenario, we consider the date on which a clini-
cian ﬁrst clinically diagnoses a rash as GVHD as onset.
Because GVHD rarely occurs before day 14 post-transplant
[10] and symptoms such as rash, nausea, and diarrhea are
often present, a conﬁdence level of “possible” is notTable 3
Biopsy Results and Conﬁdence Levels
Pathology Results Target Organ Conﬁdence Level
Treated as GVHD
Positive Conﬁrmed
Equivocal Probable
Nondiagnostic Probable
Non-GVHD etiology Probable
GVHD conﬁrmed in a biopsied target organ raises the conﬁdence level from possib
absence of treatment.entertained in this early time period. This approach de-
creases what would otherwise be many false GVHD di-
agnoses because many clinicians will consider even highly
unlikely events “possible” if not required to act on them.
However, when GVHD is diagnosed and treated, a conﬁdence
level of probable or conﬁrmed can be assigned during the
ﬁrst 2 weeks post-transplant depending onwhether GVHD is
biopsy-proven.
BIOPSY INTERPRETATION
Biopsies are often obtained to conﬁrm a GVHD diagnosis,
but experienced pathologists from different centers disagree
on the threshold of histopathologic ﬁndings that should be
present to diagnose acute GVHD [20]. Biopsy interpretation
can be further complicated by the timing of the biopsy post-
transplant and by the setting in which the symptoms arise
and may not clearly identify the etiology of GVHD-like
symptoms in up to 60% of biopsies [21,22]. These in-
consistencies can result in highly variable treatment
decision-making among clinicians, and just as we do not
attempt to inﬂuence clinical decision-making with these
research data collection guidelines, we do not intend to
dictate the clinical practice of our colleagues in pathology.
Because biopsy reports may be highly variable in their
language, we have classiﬁed the interpretation of biopsy
reports into 4 categories: non-GVHD etiology (unequivocal
evidence of a diagnosis other than GVHD without concomi-
tant features suggestive of GVHD), nondiagnostic (no abnor-
malities identiﬁed, or subtle changes noted that are
insufﬁcient to identify an etiology, or insufﬁcient tissue for
interpretation), equivocal (ﬁndings are present consistent
with GVHD and other etiologies but the pathologist cannot
deﬁnitively conﬁrm the presence of GVHD), and positive
(GVHD is clearly identiﬁed as present on the biopsy, with or
without other coexisting processes present on the biopsy).
Biopsy results are used together with the clinical treatment
decisions to assign a conﬁdence level to the attribution of
symptoms to a diagnosis of GVHD (Table 3).Not Treated but GVHD
in Differential Diagnosis
Not Treated and GVHD Not
in Differential Diagnosis
Conﬁrmed Conﬁrmed
Possible Possible
Possible Negative
Negative Negative
le to probable for other target organs where GVHD is suspected, even in the
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difﬁcult to deﬁnitively categorize, which necessitates dis-
cussion and adjudication on a multicenter call to obtain
consensus opinion. Acute GVHD remains a clinical diagnosis;
however, GVHD is considered present if it is diagnosed and
treated despite a nonconﬁrmatory biopsy. Additionally, we
developed guidance for GVHD staging when symptoms are
present in multiple target organs but only 1 has been bio-
psied. To summarize, biopsy results from 1 organ cannot
conﬁrm the presence of GVHD in another symptomatic or-
gan, but the biopsy interpretation in 1 organ may increase
the conﬁdence level for the presence of GVHD in another
organ. For example, if a patient has mild skin rash and
persistent nausea that have not been clinically diagnosed as
GVHD and a subsequent skin biopsy conﬁrms a diagnosis of
skin GVHD, the conﬁdence that the persistent nausea is due
to upper GI GVHD increases from possible to probable.
Additionally, GVHD symptoms may resolve in 1 target organ
after initiation of systemic therapy after biopsy for a separate
organ, and we consider GVHD to be probable in the non-
biopsied site unless there is compelling evidence that an
etiology other than GVHD is present (eg, documented enteric
infection).
MULTIPLE CONFIRMED ETIOLOGIES
We stage target organs solely based on symptom quan-
tiﬁcation. Some transplant centers will downgrade GVHD
clinical severity when, in addition to GVHD, another etiology
of the GVHD symptoms is documented (eg, infectious en-
teritis or hyperbilirubinemia due to sinusoidal obstruction
syndrome). We have elected not to implement this staging
rule within our consortium because it is not a standard
practice at most participating centers. We do collect the raw
symptom data for every target organ and retain the capa-
bility to restage GVHD if we choose to adopt this practice or a
new clinical staging system altogether in the future.
CLINICAL VIGNETTES
The following clinical vignettes have been selected to
illustrate the application of our clinical research data
collection guidelines. All cases are actual patients treated at
institutions participating in our consortium that were dis-
cussed during international adjudication webinars.
Clinical Case 1
A 37-year-old woman presents to the clinic on post-
transplant day 35 after an 8/8 HLA-matched unrelated
donor BMT with complaints of up to 4 watery stools daily.
She denies upper GI symptoms, her liver function tests are
within normal limits, and she has no rash. She is admitted to
the hospital for further evaluation, including stool studies for
infectious etiologies and sigmoidoscopy with biopsies.
On the day of admission, the patient’s maximal stool
output is estimated as 800 mL/day (4 stools estimated at
200mL each). Because no treatment is started and there is no
biopsy information available, the lower GI GVHD symptoms
are assigned a conﬁdence level of possible.
Sigmoid colon biopsies are obtained in post-BMT day 36.
The patient has 1300 mL of diarrhea on day 36. On day
37 the biopsy report states, “Scattered single-cell necrosis
and apoptotic debris, consistent with grade I graft-versus-
host disease.” Methylprednisolone is started at a dose of
2 mg/kg for GVHD.
In this setting the presence of lower GI GVHD is conﬁrmed
by a positive biopsy on post-BMT day 36. The highest stooloutput leading up to the diagnosis of GVHD is 1300 mL/day;
thus, lower GI GVHDwas documented as stage 2 (Table 1). Of
note, the pathologist provided a histologic grade for the
severity of GVHD seen on biopsy: Histopathologic grading
does not correlate with clinical symptom severity and does
not inﬂuence the reported clinical staging [20]. Although
symptomswere ﬁrst documented on day 35, the clinician did
not elect to stage or treat the lower GI symptoms as GVHD
before ruling out infectious causes or obtaining biopsies of
the lower GI tract. GVHD onset was thus recorded as day 36
(the date of the positive biopsy) with staging as follows: skin
0 (negative), liver 0 (negative), upper GI 0 (negative), lower
GI 2 (conﬁrmed), overall grade III.
Clinical Case 2
A 67-year-old man receives a 10/10 HLA-matched pe-
ripheral blood stem cell transplant after myeloablative con-
ditioning consisting of thiotepa, busulfan, ﬂudarabine, and
antithymocyte globulin for primary myeloﬁbrosis. He is
receiving cyclosporine and mycophenolate mofetil for GVHD
prophylaxis. He develops hyperbilirubinemia during the
conditioning regimen that persists through the early trans-
plant course, ranging from 3.9 to 6.6 md/dL, which is
attributed to conditioning regimenerelated hepatotoxicity.
On post-transplant day 10 he develops fever accompanied by
new-onset diarrhea of 2000 mL/day and an erythematous
macular rash involving his face and upper torso, determined
to be 11% BSA. His bilirubin is 4.9 on that day. The treating
clinician initiates steroids at a dose of 2 mg/kg for presumed
GVHD.
Because systemic treatment was initiated for presumed
GVHD, day 10 is considered GVHD onset. Skin and lower GI
staging at onset are 1 (11% BSA) and 3 (2000 mL/day),
respectively, and assigned a probable conﬁdence level. In this
scenario the hyperbilirubinemia was present before the
clinical diagnosis of GVHD without a signiﬁcant increase in
bilirubin levels at the onset of new GVHD symptoms, so the
liver was staged as 0 with a negative conﬁdence level and
attributed to conditioning regimen toxicity. As with signs
and symptoms present in any target organ, the total bilirubin
level is still collected for research purposes. Thus, staging
was skin 1 (probable), liver 0 (negative), upper GI 0 (nega-
tive), lower GI 3 (probable), overall grade III.
On post-transplant day 15 the rash resolved but the
diarrhea persisted, prompting an esophagogastroduodeno-
scopy to obtain biopsies reported as “histopathologic ﬁnd-
ings are limited and nonspeciﬁc; no GVHD or CMV is found.”
The 3-day average stool volume is 800 mL/day and total
bilirubin level is 2.5 mg/dL and down-trending. The clinician
continues to stage and treat the patient’s diarrhea as GVHD.
The biopsy results are interpreted as nondiagnostic,
despite the ongoing clinical symptoms; thus, the conﬁdence
levels remain probable for any active GVHD. Staging is re-
ported as skin 0 (probable), liver 0 (negative), upper GI
0 (negative), lower GI 1 (probable), overall grade II.
Clinical Case 3
A 43-year-old woman presents to the outpatient clinic
52 days after a matched related donor BMT with a new
erythematousmaculopapular rash over her face, upper chest,
and forearms after working in her garden. She has no other
symptoms of concern for GVHD. The clinician estimates the
rash involves 20% BSA and believes the rash is secondary to
sun sensitivity related to voriconazole fungal prophylaxis but
documents a lesser concern for new-onset acute GVHD. He
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topical steroid creams with close follow-up.
At this time the clinician favors a skin photosensitivity
reaction and does not make a clinical diagnosis of GVHD. The
skin rash is reported as possible GVHD but is not considered
GVHD onset because an alternative diagnosis is favored.
Upon follow-up on post-transplant day 56, the rash has
now spread to her shoulders and upper back and now in-
volves 35% BSA despite the previous interventions. She has
no other concerning ﬁndings. The clinician does not obtain a
skin biopsy but now believes the rash is due to skin GVHD
and elects to continue treatment with topical steroids.
Day 56 is considered GVHD onset, with staging reported
as skin 2 (probable), liver 0 (negative), upper GI 0 (negative),
lower GI 0 (negative), overall grade I. Although skin symp-
toms began on day 52, it is possible that the patient’s rash
was a photosensitivity reaction that later evolved into skin
GVHD, and one cannot presume that GVHD was initially
present.
The patient returns to clinic on post-transplant day 62,
and the rash now involves the entire torso, face, bilateral
forearms, and bilateral posterior thighs, reported as 60% BSA.
She does not have any other symptoms concerning for GVHD.
The clinician initiates systemic corticosteroids at a dose of
2 mg/kg.
The progression of the rash and initiation of systemic
corticosteroid therapy does not change the conﬁdence level
for the skin GVHD because there is no conﬁrmatory biopsy.
The patient’s GVHD is thus staged on day 62 as skin 3
(probable), liver 0 (negative), upper GI 0 (negative), lower GI
0 (negative), overall grade II.
DISCUSSION
Clinical data capture can prove extremely challenging in
the setting of allogeneic BMT given the multitude of com-
plications patients may experience. Our consortium believes
the guidance outlined in this report is a starting point for
standardizing data reporting across centers with varying
clinical practices and provides structure for previously un-
addressed issues for GVHD staging. It creates a systematic
approach for the determination of GVHD onset, conﬁdence in
the attribution of symptoms to acute GVHD, and quantiﬁ-
cation of clinical severity of GVHD in each target organ. These
guidelines also provide structure and categorization to the
interpretation of biopsy reports and how the inﬂuence of a
biopsy from 1 target organ guides conﬁdence in the diag-
nosis of GVHD in other symptomatic organs. Some of the
particularly challenging areas of GVHD clinical reporting,
such as determination of the presence of upper GI GVHD
without conﬁrmatory biopsy or whether to document and
stage transaminitis as liver GVHD, could be further clariﬁed
through the use of diagnostic biomarkers. Unfortunately,
although validated plasma biomarkers speciﬁc to skin and
lower GI GVHD have been identiﬁed [23,24], GVHD bio-
markers speciﬁc to the liver and upper GI tract have yet to be
identiﬁed.
Although some of the rules implemented by our con-
sortium are arbitrary, they reﬂect our consensus opinion and
are applied consistently across all participating centers. The
intent is to standardize data extraction from the medical
record without restricting autonomy of the treating clinician.
We acknowledge there are limitations in our staging guid-
ance and it does not account for every conceivable scenario.
The guidance will be further reﬁned as we encounter com-
plex issues not currently addressed. Conﬁdence levelsprovide additional granularity to the attribution of symp-
toms concerning for GVHD and may help with the retro-
spective selection (or exclusion) of patients for research and
reports and for the selection of patients for clinical trials of
GVHD therapy. Future research, by our consortium and
others, is required to determine the reliability of this clinical
data reporting tool. For example, our GVHD onset rules can
be compared with validated GVHD biomarkers in blood
samples obtained at the same time. Likewise, we can test
whether GVHD outcomes can be better predicted when
GVHD clinical severity is incorporated into a GVHD
biomarker algorithm [10].
Treatment of GVHD has remain unchanged for over
40 years; no therapies have been identiﬁed that improve
outcomes when supplementing or replacing systemic corti-
costeroid treatment, and no treatment has been shown to be
reliably effective for steroid-refractory GVHD when tested in
phase III clinical trials [23-27]. Institutional biases and
longstanding practices are difﬁcult to overcome and may
explain why the ﬁndings of single-center studies of GVHD
therapies generally have not reproduced in the multicenter
setting. Uniform clinical GVHD data reporting among centers
relies on acceptance and consistent application of clear
guidance and diligence in documentation and is a necessary
process if we are to improve future multicenter GVHD
studies. The guidance we report here has been in use inter-
nationally for 2 years and can provide much needed stan-
dardization in clinical staging for future research endeavors.ACKNOWLEDGMENTS
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